The poor overall prognosis of radioiodine refractory thyroid cancer is an inevitable challenge in managing this disease. A series of trials have demonstrated the antitumor activity of tyrosine kinase inhibitors (TKIs) in radioiodine refractory differentiated thyroid cancer (RAIR-DTC). However, the available evidence cannot determine the optimal choice of TKI in RAIR-DTC.

中文翻译：

---

酪氨酸激酶抑制剂治疗放射性碘难治性分化型甲状腺癌：系统评价和荟萃分析

放射性碘难治性甲状腺癌的总体预后不良是治疗该疾病不可避免的挑战。一系列试验证明了酪氨酸激酶抑制剂（TKI）在放射性碘难治性分化型甲状腺癌（RAIR-DTC）中的抗肿瘤活性。然而，现有证据无法确定 RAIR-DTC 中 TKI 的最佳选择。